Abstract:Abstract IMPORTANCE Genetic diseases are a leading cause of childhood mortality. Whole genome sequencing (WGS) and whole exome sequencing (WES) are relatively new methods for diagnosing genetic diseases. OBJECTIVES Compare the diagnostic sensitivity (rate of causative, pathogenic or likely pathogenic genotypes in known disease genes) and rate of clinical utility (proportion in whom medical or surgical management was changed by diagnosis) of WGS, WES, and chromosomal microarrays (CMA) in children with suspected genetic diseases. DATA SOURCES AND STUDY SELECTION Systematic review of the literature (January 2011 - August 2017) for studies of diagnostic sensitivity and/or clinical utility of WGS, WES, and/or CMA in children with suspected genetic diseases. 2% of identified studies met selection criteria. DATA EXTRACTION AND SYNTHESIS Two investigators extracted data independently following MOOSE/PRISMA guidelines. MAIN OUTCOMES AND MEASURES Pooled rates and 95% Cl were estimated with a random-effects model. Metaanalysis of the rate of diagnosis was based on test type, family structure, and site of testing. RESULTS In 36 observational series and one randomized control trial, comprising 20,068 children, the diagnostic sensitivity of WGS (0.41, 95% Cl 0.34-0.48, I 2 =44%) and WES (0.35, 95% Cl 0.31-0.39, I 2 =85%) were qualitatively greater than CMA (0.10, 95% Cl 0.08-0.12, I 2 =81%). Subgroup meta-analyses showed that the diagnostic sensitivity of WGS was significantly greater than CMA in studies published in 2017 ( P <.0001, I 2 =13% and I 2 =40%, respectively), and the diagnostic sensitivity of WES was significantly greater than CMA in studies featuring within-cohort comparisons ( P <001, I 2 =36%). Evidence for a significant difference in the diagnostic sensitivity of WGS and WES was lacking. In studies featuring within-cohort comparisons of singleton and trio WGS/WES, the likelihood of diagnosis was significantly greater for trios (odds ratio 2.04, 95% Cl 1.62-2.56, I 2 =12%; P <.0001). The diagnostic sensitivity of WGS/WES with hospital-based interpretation (0.41, 95% Cl 0.38-0.45, I 2 =50%) was qualitatively higher than that of reference laboratories (0.28, 95% Cl 0.24-0.32, I 2 =81%); this difference was significant in meta-analysis of studies published in 2017 ( P =.004, I 2 =34% and I 2 =26%, respectively). The rates of clinical utility of WGS (0.27, 95% Cl 0.17-0.40, I 2 =54%) and WES (0.18, 95% Cl 0.13-0.24, I 2 -77%) were higher than CMA (0.06, 95% Cl 0.05-0.07, I 2 =42%); this difference was significant in meta-analysis of WGS vs CMA ( P <.0001). CONCLUSIONS AND RELEVANCE In children with suspected genetic diseases, the diagnostic sensitivity and rate of clinical utility of WGS/WES were greater than CMA. Subgroups with higher WGS/WES diagnostic sensitivity were trios and those receiving hospital-based interpretation. WGS/WES should be considered a first-line genomic test for children with suspected genetic diseases. Key Points Question What is the relative diagnostic sensitivity and clinical utility of different genome tests in children with suspected genetic diseases? Findings Whole genome sequencing had greater diagnostic sensitivity and clinical utility than chromosomal microarrays. Testing parent-child trios had greater diagnostic sensitivity than proband singletons. Hospital-based testing had greater diagnostic sensitivity than reference laboratories. Meaning Trio genomic sequencing is the most sensitive diagnostic test for children with suspected genetic diseases.

Whole-Genome vs Whole-Exome Sequencing in Suspected Genetic Disorders

Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature

Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: evidence from Canada

Cost-effectiveness of exome sequencing and chromosomal microarray for low-risk pregnancies: Cost-effectiveness of Prenatal Exome Sequencing

Advantages and Perils of Clinical Whole-Exome and Whole-Genome Sequencing in Cardiomyopathy

A meta-analysis of the diagnostic sensitivity and clinical utility of genome sequencing, exome sequencing and chromosomal microarray in children with suspected genetic diseases

Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases

The usefulness of whole-exome sequencing in routine clinical practice

A cost-effective sequencing method for genetic studies combining high-depth whole exome and low-depth whole genome

Exome and Whole-Genome Sequencing As Clinical Tests: a Transformative Practice in Molecular Diagnostics.

Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test

Whole Exome Sequencing in the Researches and Diagnosis of Monogenic Disorders

Comparison of medical management and genetic counseling options pre- and post-whole exome sequencing for patients with positive and negative results.

Assessing the Costs and Cost-Effectiveness of Genomic Sequencing

Clinical application of whole-exome sequencing across clinical indications

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

Rapid Genome Sequencing Compared to a Gene Panel in Infants with a Suspected Genetic Disorder: An Economic Evaluation

Whole Genome Sequencing in the Evaluation of Fetal Structural Anomalies: A Parallel Test with Chromosomal Microarray Plus Whole Exome Sequencing

Promises, pitfalls and practicalities of prenatal whole exome sequencing

Diagnostic yield of exome and genome sequencing after non-diagnostic multi-gene panels in patients with single-system diseases

Whole Exome Sequencing as a First-Line Molecular Genetic Test in Developmental and Epileptic Encephalopathies